<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" bill-type="olc" dms-id="HD42ECADABB664996892214CDBD69961F" public-private="public">
	<metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>113 HR 594 IH: Paul D. Wellstone Muscular Dystrophy Community Assistance, Research and Education Amendments of 2013</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2013-02-08</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
		<distribution-code display="yes">I</distribution-code>
		<congress>113th CONGRESS</congress>
		<session>1st Session</session>
		<legis-num>H. R. 594</legis-num>
		<current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber>
		<action>
			<action-date date="20130208">February 8, 2013</action-date>
			<action-desc><sponsor name-id="B001248">Mr. Burgess</sponsor> (for
			 himself and <cosponsor name-id="E000179">Mr. Engel</cosponsor>) introduced the
			 following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and
			 Commerce</committee-name></action-desc>
		</action>
		<legis-type>A BILL</legis-type>
		<official-title>To reauthorize and extend the Paul D. Wellstone Muscular
		  Dystrophy Community Assistance, Research, and Education Amendments of
		  2008.</official-title>
	</form>
	<legis-body id="H2BAAAC42F3F742068383B6E82543DEAF" style="OLC">
		<section id="H13E31C7C9572417482BA0B0F2049223B" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the
			 <quote><short-title>Paul D. Wellstone Muscular Dystrophy
			 Community Assistance, Research and Education Amendments of
			 2013</short-title></quote>.</text>
		</section><section id="H130E50A948EB4DF7A8041BE3ECAFFEEF"><enum>2.</enum><header>Initiative
			 through the Director of the National Institutes of Health</header><text display-inline="no-display-inline">Section 404E of the Public Health Service
			 Act (<external-xref legal-doc="usc" parsable-cite="usc/42/283g">42 U.S.C. 283g</external-xref>) is amended—</text>
			<paragraph id="H0C30A905346648A19207FA507A29AE86"><enum>(1)</enum><text>in subsection
			 (a)(1)—</text>
				<subparagraph id="H01ED06EB6D034E3DBE666CAABA9EB790"><enum>(A)</enum><text>by striking
			 <quote>Muscoskeletal</quote> and inserting <quote>Musculoskeletal</quote>;
			 and</text>
				</subparagraph><subparagraph id="H2197951EE46344BFBAD8DA3ABD0DBD70"><enum>(B)</enum><text>by inserting
			 <quote>Becker, myotonic, facioscapulohumeral muscular dystrophy (referred to in
			 this section as <quote>FSHD</quote>), Congenital muscular dystrophy,
			 Limb-girdle muscular dystrophy,</quote> after <quote>Duchenne,</quote>;</text>
				</subparagraph></paragraph><paragraph id="H31AD9F841FDE48D5A3633CF39A36EA0E"><enum>(2)</enum><text>in subsection
			 (b)—</text>
				<subparagraph id="H600443C033FE4C469EC45D955B10ECD8"><enum>(A)</enum><text>in paragraph (2),
			 by inserting <quote>cardiac and pulmonary function,</quote> after
			 <quote>imaging, genetics,</quote>; and</text>
				</subparagraph><subparagraph id="H695DEB9D1E404738A9C6986C1FDF9FFD"><enum>(B)</enum><text>in paragraph (3),
			 by inserting <quote>and sharing of data</quote> after <quote>regular
			 communication</quote>;</text>
				</subparagraph></paragraph><paragraph id="HDDB96A8B4A4F424483FB706CC49A16CB"><enum>(3)</enum><text>in subsection
			 (d)—</text>
				<subparagraph id="H81F7D9FFEFBD4E71AF0BD19D78C26053"><enum>(A)</enum><text>in paragraph
			 (2)—</text>
					<clause id="H6DDF591348B74FBC9F7D9BAC01AFF9A4"><enum>(i)</enum><text>in
			 the matter preceding subparagraph (A), by striking <quote>15</quote> and
			 inserting <quote>18</quote>; and</text>
					</clause><clause id="H584919F2D08E4889B730ABC08443D1FD"><enum>(ii)</enum><text>in
			 subparagraph (A), by striking <quote>children with muscular dystrophy, such as
			 the Department of Education</quote> and inserting <quote>children and adults
			 with muscular dystrophy, such as the Department of Education, the Social
			 Security Administration, the United States Administration for Community
			 Living</quote>; and</text>
					</clause></subparagraph><subparagraph id="H447D27C628FF4E4792BF9D7300618A15"><enum>(B)</enum><text>in paragraph
			 (4)(B), by inserting <quote>, and shall meet no less than two times per
			 calendar year</quote> before the period;</text>
				</subparagraph></paragraph><paragraph id="H5009481BAB3C4FA99212BE3C0976CCAB"><enum>(4)</enum><text>in subsection
			 (e)—</text>
				<subparagraph id="HF5331F5EAF7647DF8CB1D410AF327DA7"><enum>(A)</enum><text>in paragraph
			 (1)—</text>
					<clause id="H8012962F41284899B793C60D0BB26C7C"><enum>(i)</enum><text display-inline="yes-display-inline">in the matter preceding subparagraph (A),
			 by striking <quote>through the national research institutes</quote> and
			 inserting <quote>through the agencies represented on the Coordinating Committee
			 pursuant to subsection (d)(2)(A)</quote>; and</text>
					</clause><clause id="H0F57C865E3354CD781CC701B6504C2A3"><enum>(ii)</enum><text>in
			 subparagraph (A), by striking <quote>and rehabilitative issues, including
			 studies of the impact of such diseases in rural and underserved
			 communities</quote> and inserting <quote>public resources, and rehabilitative
			 issues, including studies of the impact of such diseases in rural and
			 underserved communities, health economic studies to demonstrate the
			 cost-effectiveness of providing independent living resources and support to
			 patients with various forms of muscular dystrophy, and studies to determine
			 optimal clinical care interventions for adults with various forms of muscular
			 dystrophy</quote>; and</text>
					</clause></subparagraph><subparagraph id="HF046F61FB43F44D88BD69C88F49FE7DB"><enum>(B)</enum><text>in paragraph (2),
			 by adding at the end the following:</text>
					<quoted-block display-inline="no-display-inline" id="H20F5A5A6FA52492787AC92F305DE3736" style="OLC">
						<subparagraph id="HFACB9EA55EAC48D08875B8D5B7D09CD7"><enum>(F)</enum><text>The development of
				clinical interventions to improve the health of adults with various forms of
				muscular dystrophy.</text>
						</subparagraph><after-quoted-block>;
				and</after-quoted-block></quoted-block>
				</subparagraph></paragraph><paragraph id="H2EEDDCEDBE4A44D8A45C0ECD35ABE1E5"><enum>(5)</enum><text>in subsection (g),
			 by striking <quote>for the various forms of muscular dystrophy by prioritizing
			 the achievement of the goals related to this topic in the plan under subsection
			 (e)(1)</quote> and inserting <quote>and shall, not later than 6 months after
			 the date of enactment of the <short-title>Paul D.
			 Wellstone Muscular Dystrophy Community Assistance, Research and Education
			 Amendments of 2013</short-title>, in coordination with appropriate Federal
			 agencies, including relevant offices within the Food and Drug Administration
			 and supported by the National Institutes of Health and Department of Defense,
			 develop a plan to expedite the evaluation and approval of emerging therapies
			 and personalized medicines that have the potential to decrease fatal disease
			 progression across the various forms of muscular dystrophy</quote>.</text>
			</paragraph></section><section id="H969FA034327C49A198B02EE9A67CC116"><enum>3.</enum><header>Surveillance and
			 research regarding muscular dystrophy</header><text display-inline="no-display-inline">Section 317Q of the Public Health Service
			 Act (<external-xref legal-doc="usc" parsable-cite="usc/42/247b-18">42 U.S.C. 247b–18</external-xref>) is amended—</text>
			<paragraph id="H2CDD18E1D2A84BB08D8FEB0F748E683A"><enum>(1)</enum><text>in the second
			 sentence of subsection (b), by inserting before the period the following:
			 <quote>and ensure that the program captures data from different racial and
			 ethnic populations, and that such data are made publicly available to
			 investigators conducting public or private research on muscular
			 dystrophy</quote>; and</text>
			</paragraph><paragraph id="H5E33ADD94B724159A40DEFF0885C5259"><enum>(2)</enum><text>in subsection (c),
			 by adding at the end the following: <quote>The Secretary shall also foster
			 ongoing engagement and collaboration between the surveillance program and
			 centers of excellence.</quote>.</text>
			</paragraph></section><section id="HE20E624237D14F3D871C90793365F9AA"><enum>4.</enum><header>Information and
			 education</header><text display-inline="no-display-inline">Section 5(c) of the
			 Muscular Dystrophy Community Assistance, Research and Education Amendments of
			 2001 (<external-xref legal-doc="usc" parsable-cite="usc/42/247b-19">42 U.S.C. 247b–19(c)</external-xref>) is amended by adding at the end the
			 following:</text>
			<quoted-block display-inline="no-display-inline" id="HBB660D630A8C4C59ABD600591CF0E640" style="OLC">
				<paragraph id="H8B106909FAC749DCAFE7D224D377B4E3"><enum>(4)</enum><text display-inline="yes-display-inline">Update and widely disseminate existing
				Duchenne-Becker muscular dystrophy care considerations for pediatric patients,
				develop and widely disseminate Duchenne-Becker muscular dystrophy care
				considerations for adult patients, and develop and widely disseminate acute
				care considerations for all muscular dystrophy populations. The care
				considerations should build upon existing efforts currently underway for
				congenital muscular dystrophy, fascioscapulohumeral muscular dystrophy,
				limb-girdle muscular dystrophy, and myotonic muscular dystrophy, and
				incorporate strategies specifically responding to the findings of the national
				transitions survey of minority, young adult and adult communities of muscular
				dystrophy
				patients.</text>
				</paragraph><after-quoted-block>.</after-quoted-block></quoted-block>
		</section></legis-body>
</bill>


